The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report

• Published in: Medicine (Baltimore) Vol. 97; no. 25; p. e11214
• Main Authors: Zhu, Hong, Ma, Xiaojun, Zhao, Yaqin, Duo, Ji
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health 01.06.2018
• Subjects: Adult; Carcinoma, Hepatocellular - diagnostic imaging; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; Chemoembolization, Therapeutic - methods; Clinical Case Report; Disease Progression; Fatal Outcome; Humans; Liver Neoplasms - diagnostic imaging; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Lung - diagnostic imaging; Lung - microbiology; Lung - pathology; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - pathology; Lung Neoplasms - secondary; Male; Neoplasm Metastasis - drug therapy; Niacinamide - administration & dosage; Niacinamide - analogs & derivatives; Niacinamide - therapeutic use; Phenylurea Compounds - administration & dosage; Phenylurea Compounds - therapeutic use; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Pyridines - administration & dosage; Pyridines - pharmacology; Pyridines - therapeutic use; Sorafenib; Tomography, X-Ray Computed - methods
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000011214

Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. Although sorafenib is currently recommended as standard treatment for advanced HCC, its treatment efficacy is limited. Effective treatments for patients with advanced HCC that progresses on or after sorafenib treatment or patients who are intolerant of sorafenib remain an unmet medical need. We report an advanced HCC patient with many lung metastases who failed sorafenib treatment. Sorafenib refractory HCC patient with a large number of lung metastases. The apatinib alone was used as second line therapy. The patient achieved partial response (PR) soon after the treatment, which was maintained for approximately 1 year. During the entire process, the lung metastases continued to diminish. Finally, only a few lesions remained LESSONS:: Apatinib alone may be a good second-line therapy for advanced HCC patients who are refractory to sorafenib. However, further investigation in future prospective clinical studies is warranted.